EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 June 24, 2021 Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom... May 29, 2019 Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... March 31, 2021 Load more HOT NEWS ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell...
